HGSI (NASDAQ), Leerink Swann upped t.p. to 30 usd, stock up to 16 usd

STAA (NASDAQ)  up 7% 

TSPT(NASDAQ), OREX (NASDAQ), MITI (NASDAQ), CLDA (NASDAQ) in green

AVNR (NASDAQ) is a strong buy after Zenvia study meets goal:
In the late-stage study, Zenvia reduced emotional outbursts by 47.2 percent, compared with placebo. That topped the goal of the study, which was a 36 percent reduction

Trading-news firmly hold the position on AVNR (NASDAQ), short attack won't invalidate strong underlying fundamental news above. We think  the stock will move higher in the near term.

We sold ISTA (NASDAQ) with 25% gain

TICKER            BUY AREA   QUOTE NOW   POSITION           DRIVER

AVNR (NASDAQ) USD 3,8               2,9               LT           ZENVIA
BMTI (NASDAQ) USD 10,8          10,6              LT           PENDING CLINICAL DATA
OREX (NASDAQ) USD 7,7           7,7            LT                 CONTRAVE
DYAX (NASDAQ) USD 3,7           3,6           LT           DX-88 FDA PDUFA 12/1/09
THRX (NASDAQ) 15                14,1           SHORT TERM   FDA PDUFA Telavancin on 9/16/09
VVUS (NASDAQ)USD 6,9 USD      7                LT         STRONG CONSENSUS, PENDING DATA
HGSI (NASDAQ) USD 14,42       15,8                LT      LUPUS DRUG SUCCESSFUL
ARNA (NASDAQ) USD 5,05       4,4       SHORT TERM PENDING SEPTEMBER CLINICAL DATA
SQNM (NASDAQ) USD 5,85    6,35(+8%) SOLD
TSPT (NASDAQ) USD 7,8          8,75       LT INTERMEZZO PENDING FDA APPROVAL-PARTNERSHIP
ALXA (NASDAQ) USD 2,28         2,4            LT                 STRONG CONSENSUS
CYTK (NASDAQ) USD 3           2,92           LT    STRONG CONSENSUS PENDING CLINICAL DATA
ARIA (NASDAQ) USD 2,35    1,90 SOLD (-19%)
AEZS(NASDAQ) USD 2,1        2,53 (+20%)            LT   STRONG CONSENSUS, PENDING DATA
JAV (AMEX)   USD 1,3          1,98 SOLD(+55%)
NPSP (NASDAQ) USD 4,7     4,15               LT              STRONG CONSENSUS
ONXX(NASDAQ) USD 35,9    31,35                LT                     OVERSOLD
IDIX (NASDAQ) USD 4,44        4,2 SOLD(-5%)
SNTS (NASDAQ) USD 2,81    3,25 SOLD(+17%)
BFRM (NASDAQ) USD 2,85   3,2        LONG TERM        FDA APPROVED RADIESSE(r) Dermal Fill
OCLS (NASDAQ) USD 2,85    2,45 SOLD (-15%)
TRGT (NASDAQ) USD 5,5     8,7 SOLD(+60%)
OREX (NASDAQ) USD 5,35    6,45 SOLD(+20%)
FOLD (NASADQ) USD 10    10       LONG TERM       PLICERA, AMIGAL, STRONG CONSENSUS
SOMX (NASDAQ) USD 1,10  1,38 SOLD (+25%)
DDSS (NASDAQ) USD 2,65    1,7      HOLD                            TRAZODONE 
XNPT (NASDAQ) USD 21,85  19,6   LONG TERM            XP19986 POSITIVE TRIAL 6/30/09
VNDA (NASDAQ) USD12,1    15,2 SOLD (+25%)
CYTR (NASDAQ) USD 1,02    0,95     LONG TERM                 STRONG CONSENSUS
JAZZ (NASDAQ) USD 4,95   7,3 SOLD (+45%)
PARD (NASDAQ) USD 5    5,9 PROFIT TAKING(+18%)
PARD (NASDAQ) USD 6,6  rebought 7/2 7,2 SOLD (+9%)
INCY (NASDAQ) USD 3,5      5,2    SOLD (+50%)
ISTA (NASDAQ) USD 4,1         5,15 (+ 25%)                  
SLXP (NASDAQ) USD 9,9   12,55 SOLD(+25%)
MAPP (NASDAQ) USD 11,3  9,7    REBUYING LONG TERM        STRONG CONSENSUS
ARYX (NASDAQ) USD 4,5    SOLD 2,5 (-45%)
ARRY (NASDAQ) USD 3,1    4,2 SOLD (+30%)
GTXI (NASDAQ) USD 9,5  9,3        LONG TERM FDA                   PDUFA 10/30/09
UTHR (NASDAQ) USD 84    96 SOLD (+15%)
NGSX (NASDAQ) USD 6,4    8,2 SOLD(+30%)
VICL (NASDAQ) USD 3      3,4         LONG TERM                            SWINE FLU
STAA (NASDAQ) USD 3,3 2,9         LONG TERM               FDA CLEARENCE FOR Epiphany(TM)
ALTH (NASDAQ) 7,9      8,1         LONG TERM              FDA PDUFA 9/24/09, PANEL REVIEW 9/2/09
AMAG (NASDAQ) 52,8   44           LONG TERM           FDA APPROVES FERAHEME 6/30/09
XOMA (NASDAQ) 1,2    0,85           LONG TERM                            OVERSOLD
HEB (AMEX) 3,3(5%OF CAPITAL) 2,25 SOLD(-35%)
HEB (AMEX) was rebought after 100% gain (see old posts)
MRNA (NASDAQ) 3,3           1,4 SOLD (-55%)
RIGL (NASDAQ) USD 10        10,1 SOLD FLAT
MITI (NASDAQ) USD 6    6,22          LONG TERM                  STRONG CONSENSUS            
MNKD (NASDAQ) USD 8,3     7,95 SOLD(-4%)
SVNT (NASDAQ) USD 7,10     13 SOLD(+90%)
NPSP (NASDAQ) 3,1 USD      4,75 SOLD(+50%)
SCLN (NASDAQ) 2,25 USD      2,7 SOLD (+20%) 
MAPP (NASDAQ) 8 USD (posts from 5/26) PROFIT TAKED(+45%) LEVADEX
VNDA (NASDAQ) 8 USD (see old post 5/8) PROFIT TAKED(+80%) FANAT
CLDA (NASDAQ) 15,7 USD 14,4           LONG TERM
CTIC (NASDAQ) 2,10 USD    1,39 SOLD (-35%)
ANPI (NASDAQ) 2 USD         1,39 SOLD(-30%)
MEDX (NASDAQ) 7,5 USD     8,7 PROFIT TAKING(+20%)
MNTA (NASDAQ) 8,9 USD    9,7             LONG TERM                   STRONG CONSENSUS
ACAD (NASDAQ) 2,6 USD      5 SOLD (+95%)
ACOR (NASDAQ) 24 USD        23,5 SOLD (-2%) FAMPRIDINE-SR, FDA PDUFA 10/22/09
BDSI (NASDAQ) USD 5,45    PROFIT TAKED 6,3 (+18%)
BDSI (NASDAQ) 6,6  rebought at 4,9      SHORT TERM         ONSOLIS APPROVED BY FDA
DNDN (NASDAQ) 22 USD (see old post 4/27)  23,2 LONG TERM             PROVENGE
SPPI (NASDAQ) 4 USD    (see ols post 5/12) 6/12 PROFIT TAKING (+35%)
SPPI (NASDAQ) 5,85 USD          7,4 PROFIT TAKING(+28%)
SPPI (NASDAQ) 6,5 USD rebought 7/2 6,8 LT ZEVALIN FDA PDUFA 09/07/09 FUSILEV PDUFA 08/10/09